Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 314.50 | 318.00 | 307.00 | +5.50 | +1.78% | 893.00K | London | |||
| 50.80 | 51.40 | 48.70 | +1.00 | +2.01% | 4.01M | London | |||
| 2.00 | 2.00 | 1.59 | +0.48 | +32.65% | 33.69M | London | |||
| 2.35 | 2.49 | 2.34 | -0.045 | -1.89% | 4.77M | London | |||
| 378.20 | 383.80 | 374.20 | +7.30 | +1.97% | 13.31M | London | |||
| 803.00 | 805.00 | 793.00 | +18.00 | +2.29% | 44.08K | London | |||
| 108.00 | 108.20 | 106.20 | +1.00 | +0.94% | 384.18K | London | |||
| 5.43 | 5.50 | 4.96 | +0.40 | +7.84% | 2.35M | London | |||
| 3.60 | 3.60 | 3.60 | +0.200 | +5.88% | 2.42M | London | |||
| 691.50 | 703.00 | 687.00 | +8.50 | +1.25% | 451.57K | London | |||
| 171.50 | 177.10 | 171.15 | -2.80 | -1.61% | 6.25M | London | |||
| 1,558.00 | 1,580.00 | 1,556.00 | -6.00 | -0.38% | 2.40M | London | |||
| 2,683.50 | 2,731.00 | 2,644.00 | +48.5 | +1.84% | 3.48M | London | |||
| 7,962.00 | 8,024.00 | 7,894.00 | +114.0 | +1.45% | 214.59K | London | |||
| 183.28 | 187.32 | 183.28 | +1.62 | +0.89% | 37.36M | London |